Premenstrual syndrome

被引:378
作者
Yonkers, Kimberly Ann [1 ,2 ,3 ]
O'Brien, P. M. Shaughn [4 ]
Eriksson, Elias [5 ]
机构
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA
[3] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06510 USA
[4] Keele Univ, Sch Med, Univ Hosp N Staffordshire, Stoke On Trent, Staffs, England
[5] Univ Gothenburg, Dept Pharmacol, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0140-6736(08)60527-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most women of reproductive age have some physical discomfort or dysphoria in the weeks before menstruation. Symptoms are often mild, but can be severe enough to substantially affect daily activities. About 5-8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also meet criteria for premenstrual dysphoric disorder (PMDD). Mood and behavioural symptoms, including irritability, tension, depressed mood, tearfulness, and mood swings, are the most distressing, but somatic complaints, such as breast tenderness and bloating, can also be problematic. We outline theories for the underlying causes of severe PMS, and describe two main methods of treating it: one targeting the hypothalamus-pituitary-ovary axis, and the other targeting brain serotonergic synapses. Fluctuations in gonadal hormone levels trigger the symptoms, and thus interventions that abolish ovarian cyclicity, including long-acting analogues of gonadotropin-releasing hormone (GnRH) or oestradiol (administered as patches or implants), effectively reduce the symptoms, as can some oral contraceptives. The effectiveness of serotonin reuptake inhibitors, taken throughout the cycle or during luteal phases only, is also well established.
引用
收藏
页码:1200 / 1210
页数:11
相关论文
共 177 条
  • [1] ACOG, 2001, INT J GYNECOL OBSTET, V73, P183, DOI DOI 10.1016/S0020-7292(01)00400-3
  • [2] American Psychiatric Association, 1980, Diagnostic and statistical manual of mental disorders: DSM-IV-TR, V3rd
  • [3] ANDERSCH B, 1986, Journal of Psychosomatic Obstetrics and Gynecology, V5, P39, DOI 10.3109/01674828609016741
  • [4] ANDERSCH B, 1978, BRIT J OBSTET GYNAEC, V85, P546
  • [5] Andersch B, 1983, Obstet Gynecol Surv, V38, P643, DOI 10.1097/00006254-198311000-00001
  • [6] The epidemiology of perimenstrual psychological symptoms
    Angst, J
    Sellaro, R
    Stolar, M
    Merikangas, KR
    Endicott, J
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (02) : 110 - 116
  • [7] [Anonymous], INT J GYNAECOLOGY S3
  • [8] ASLAKSEN K, 1991, CURR THER RES CLIN E, V49, P120
  • [9] THE USE OF AN LHRH AGONIST, BUSERELIN, IN THE LONG-TERM MANAGEMENT OF PREMENSTRUAL SYNDROMES
    BANCROFT, J
    BOYLE, H
    WARNER, P
    FRASER, HM
    [J]. CLINICAL ENDOCRINOLOGY, 1987, 27 (02) : 171 - 182
  • [10] BLUNTING OF NEUROENDOCRINE RESPONSES TO INFUSION OF L-TRYPTOPHAN IN WOMEN WITH PERIMENSTRUAL MOOD CHANGE
    BANCROFT, J
    COOK, A
    DAVIDSON, D
    BENNIE, J
    GOODWIN, G
    [J]. PSYCHOLOGICAL MEDICINE, 1991, 21 (02) : 305 - 312